Evidence map›Paper›PMID 37021190›Full record

Trial reportEuropean stroke journal2023

Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial.

Adam Edward Lang, Adam de Havenon, Brian Mac Grory, Nils Henninger, Liqi Shu, Karen L Furie, J Donald Easton, Anthony Kim, S Claiborne Johnston, Shadi Yaghi

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European stroke journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Adam Edward LangDepartment of Primary Care, McDonald Army Health Center, Fort Eustis, VA, USA.ORCID 0000-0002-4347-6514
Adam de HavenonDepartment of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0001-8178-8597
Brian Mac GroryDepartment of Neurology, Duke University School of Medicine, Durham, NC, USA.
Nils HenningerDepartment of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.
Liqi ShuDepartment of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Karen L FurieDepartment of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA.
J Donald EastonDepartment of Neurology, University of California, San Francisco, Sandler Neurosciences Center, San Francisco, CA, USA.
Anthony KimDepartment of Neurology, University of California, San Francisco, Sandler Neurosciences Center, San Francisco, CA, USA.
S Claiborne JohnstonDell Medical School, University of Texas at Austin, Austin, TX, USA.
Shadi YaghiDepartment of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Brown University · USUniversity of California, San Francisco · USDuke University · USThe University of Texas at Austin · USUniversity of Massachusetts Chan Medical School · USUniversity of Utah · USVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The aim of this study was to determine the effect of smoking status on subsequent stroke risk in patients with minor ischemic stroke or TIA and to determine whether smoking modifies the effect of clopidogrel-based DAPT on subsequent stroke risk. Methods: This was a post-hoc analysis of the Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, which had a 90-day follow-up period. We used multivariable Cox regression and subgroup interaction analysis to determine the effect of smoking on the risk of subsequent ischemic stroke and major hemorrhage, respectively. Results: Data from 4877 participants enrolled in the POINT trial were analyzed. Among these, 1004 were current smokers and 3873 were non-smokers at the time of index event. Smoking was associated with a non-significant trend toward an increased risk of subsequent ischemic stroke during follow up (adjusted HR, 1.31 (95% CI, 0.97-1.78), Conclusions: In this post-hoc analysis of the POINT trial we found that the effect of clopidogrel on reducing subsequent ischemic stroke as well as risk of major hemorrhage did not depend on smoking status, indicating that smokers benefit to a similar degree from DAPT as non-smokers.

Indexed as

Ischemic Attack, TransientIschemic StrokeStrokeAspirinClopidogrelHemorrhageHumansNeoplasm Recurrence, LocalPlatelet Aggregation InhibitorsSmokingTobacco SmokingAspirinClopidogrelPlatelet Aggregation InhibitorscigarettesclopidogrelSmokingstroketobacco

Identifiers

PMID37021190
PMCPMC10069178
OpenAlexW4313331253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.